Preclinical Toxicology Study Report & Data Integration
Synthesize preclinical toxicology data into GLP-compliant regulatory reports
What You Can Do
You consolidate parallel data streams from preclinical toxicology studies (clinical pathology, histopathology, body weight changes, organ weights, clinical observations, mortality) into coherent regulatory-compliant narratives. This skill synthesizes findings across 6–12 endpoints simultaneously, identifies NOAEL/LOAEL with biological justification, determines safety margins, interprets species-specific or sex-specific signals, and produces Results & Discussion sections that satisfy FDA/EMA reviewers while supporting appropriate dosing decisions for IND-enabling studies.
Features
integrates clinical pathology, histopathology, organ weights, and mortality into unified safety assessment
identifies no-observed-adverse-effect levels with transparent dose-response justification across mixed signals
translates preclinical findings into human-equivalent doses and quantified hazard characterization
evaluates recovery vs. non-recovery observations to assess effect persistence and potential clinical risk
identifies and explains biological mechanisms behind strain, species, or sex differences
produces Results & Discussion text formatted for FDA/EMA briefing packages with defensible conclusions
highlights missing dose groups, outliers, or conflicting signals requiring investigation before report finalization
proposes biologically plausible explanations linking organ-level findings to systemic effects
Example Output
Example 1: 28-Day Rat Study Integration
- Input: Liver weight +15% at high dose; ALT/AST elevated 2–3× at high and mid doses; centrilobular hepatocyte hypertrophy at high dose; normal recovery at 14-day post-study checkpoint
- Output: "Liver hypertrophy at high dose (≥150 mg/kg) was associated with mild transaminase elevation and reversible histologic change (centrilobular hepatocyte hypertrophy), consistent with adaptive enzyme induction. Recovery observed post-study indicates non-progressive effect. NOAEL: 50 mg/kg; LOAEL: 150 mg/kg."
Example 2: Dog Study with Sex Difference
- Input: Anemia (Hgb drop 12%) in females at high dose; males unaffected; mild bone marrow hypoplasia in one female; kidney tubular protein casts in both sexes at mid and high dose
- Output: "Female-specific anemia at ≥300 mg/kg, accompanied by bone marrow hypoplasia in one animal, suggests sex-dependent hematotoxicity. Kidney findings (tubular casts) appeared in both sexes, indicating common nephrotoxic potential. Safety margin calculation applies female-specific LOAEL (300 mg/kg) with 10-fold inter-species adjustment."
Example 3: Chronic Study Hazard Summary
- Output table: Organ system | Finding | Dose (mg/kg) | Reversibility | Mechanism | Regulatory Impact
What's Included
- SKILL.md: complete instruction file with data integration workflow, NOAEL/LOAEL decision trees, and regulatory compliance checkpoints
- Multi-endpoint consolidation template: structured worksheet mapping clinical pathology, histopathology, organ weights, and clinical observations into unified findings table
- NOAEL/LOAEL determination framework: step-by-step logic for identifying thresholds across mixed dose-response signals with transparency
- Safety margin calculation checklist: formulae and species/sex adjustment factors (FDA guidance-aligned) for human-equivalent dose translation
- Results & Discussion outline: pre-formatted sections (Methods summary, Findings by organ system, NOAEL/LOAEL justification, Reversibility assessment, Hazard characterization) ready for regulatory submission
Who It's For
- Preclinical toxicologists — synthesizing study data into regulatory-grade reports for acute, subacute, and chronic safety assessments
- IND-enabling program leads — consolidating findings from multiple toxicology studies to support investigational new drug applications
- Drug safety scientists — translating organ-level findings into human risk assessment and hazard characterization for briefing packages
- Regulatory affairs specialists — preparing preclinical sections of FDA submissions (IND, NDA, IMPD) with defensible NOAEL/LOAEL conclusions
- Contract research organization (CRO) report writers — standardizing multi-study data synthesis and reducing manual narrative generation time
Best For
- 28–90-day repeat-dose toxicology studies — rat and dog safety assessment with complex, multi-parameter datasets
- NOAEL/LOAEL determination — translating mixed dose-response signals into justified threshold identification
- Reversibility and recovery assessment — evaluating post-study observation data to assess effect persistence and potential clinical risk
- Species or sex-specific finding interpretation — explaining biological mechanisms behind strain, species, or sex differences
- Regulatory briefing document generation — producing Results & Discussion sections that satisfy FDA/EMA technical review standards
You might also like
This skill organizes complex toxicology datasets, clinical adverse events, and mechanistic findings into structured, FDA/EMA-compliant safety narratives. You input raw safety data—adverse event summaries, laboratory results, animal study findings, vital signs—and receive draft safety summaries, detailed safety assessments, and expedited safety reports ready for regulatory submission. It handles IND applications, annual safety updates, clinical development safety overviews, and urgent safety communications with proper MedDRA coding and regulatory formatting.
by kody-w
You can submit tool designs—drawings, specifications, or descriptions—and Claude will evaluate manufacturability constraints, identify potential failure modes using structured frameworks, and recommend cost-reduction opportunities. You'll receive a prioritized report covering structural analysis, production feasibility, material efficiency, and design trade-offs.
by kody-w
You can take unstructured monitoring visit observations and convert them into formal, audit-ready reports that categorize findings by risk level (Critical, Major, Minor), validate protocol compliance, and generate actionable follow-up items with assigned owners and resolution dates. The skill ensures your documentation meets FDA inspection standards and ICH-GCP requirements while creating clear escalation pathways for high-risk issues.
by kody-w
You can automate the validation of clinical trial data against protocol specifications, identify discrepancies including missing values, out-of-range results, protocol violations, and CRF inconsistencies. The skill generates audit-ready query documentation, categorizes anomalies by severity and type, resolves root causes systematically, and produces FDA inspection-ready reports that trace every data decision and corrective action for CDISC and regulatory submission.
by kody-w
You can submit raw mass spectrometry observations, instrument parameters, or sample preparation details to Claude and receive targeted diagnostic frameworks that explain anomalous results. Claude systematically generates plausible mechanistic explanations for unexpected protein abundance patterns, quantification inconsistencies, and PTM findings—then helps you design minimal, hypothesis-driven troubleshooting experiments to test them.
by kody-w
You can validate eCRF and paper CRF datasets against protocol-defined rules, automatically identify data discrepancies (missing fields, out-of-range values, date inconsistencies), generate structured Data Query Forms (DQFs) for site clarification, track resolution status, and create audit-ready compliance documentation that meets FDA 21 CFR Part 11 and GCP requirements. This workflow reduces manual validation time while ensuring 100% traceability and regulatory readiness for inspections.
by kody-w
Get comprehensive PCB design analysis covering power delivery networks, signal integrity, thermal management, and manufacturing constraints. Claude identifies potential issues early and provides specific, actionable optimization recommendations to reduce cost, improve reliability, and accelerate time-to-market. Suitable for designs from initial concept through production-ready layouts.
by kody-w
This skill systematically analyzes your product designs to identify manufacturability issues early, saving costly revisions and manufacturing delays. It evaluates geometry, material selection, tolerances, assembly feasibility, and production process constraints. You get actionable feedback on cost drivers, process risks, and design optimizations before committing to production.
by kody-w